SUMMARY The electrophysiological effects of L 9394 (benzoyl-indolizine), a substance chemically related to amiodarone, but devoid of iodine atoms, were investigated by programmed electrical stimulation of the heart in 12 patients with various forms of tachycardia. Four subjects had electrocardiographic evidence of the WPW syndrome and episodes of circus movement tachycardia. Paroxysmal supraventricular tachycardia, confined to the atrioventricular (AV) node, was found in 3 patients. In 2 cases, where a short PR interval was present, the main complaint was the occurrence of paroxysmal atrial fibrillation. In the remaining 3 instances, the arrhythmia consisted of slow ventricular tachycardia (1 case), supraventricular tachycardia of the focal type (1 case), and episodes of primary ventricular fibrillation, not related to acute myocardial ischaemia (1 case).
Amiodarone has been reported to be an effective antiarrhythmic agent for different types of arrhythmia (Coumel et al., 1974; Rosenbaum et al., 1974; Touboul et al., 1975; Rosenbaum et al., 1976; Wellens et al., 1976; Waleffe et al., 1978) . Sideeffects however have limited wide acceptance of the drug in clinical practice (Geerts, 1971; Verin et al., 1971; Babel and Stangos, 1973; Pritchard et al., 1975; Burger et al., 1976) . L 9394, a benzoylindolizine derivative, is a new substance which is chemically related to amiodarone (Fig. 1) (Charlier " right ventricle and was used for ventricular stimulation.
In 6 patients, in order to record a left atrial electrogram, a fourth quadripolar catheter was advanced into the coronary sinus or, through a patent foramen ovale, into the left atrial cavity.
Using the extrastimulus technique, the effective refractory period of the right atrium, the effective and functional refractory periods of the AV node, and the effective refractory period of the right ventricle and of the accessory pathway, when present, were measured. The zones of premature beat intervals resulting in atrial echoes or sustained tachycardia were carefully determined. The right ventricle was paced up to its effective refractory period. The pattern and refractory period of VA conduction were registered. Atrial and ventricular pacing were first done at rates slightly above the spontaneous rate, and thereafter at shorter cycle lengths. -220  300  80   2  550  50  60  10  35  35  215  235  20  < 225  360  > 135  500  3  470  70  100  30  40  40  210  230  20  < 230  330  > 100  4  600  50  70  20  20  20  210  225  15  < 235  340  > 105  5  470  100  115  15  30*  30*  175  215  40  < 200  420  22C  6  500  80  85   5   30t  30t   195  210  15  240  > 280  > 4C  7  600  100  ?  ?  -40  ?  250  270  20  ?  ?  ?   8  550  ?  ?  ?  50*  ?  210   210  0  < 240  > 310  > 7C  9  500  110   120/240 10/130   30  30  240  280  40  250  380  13C  10  500  110  140  30  30  30  170  190  20  230  330   lOC  550  11  600  120  170  50  40   40  230  250  20  < 250  420  > 17C  12  500  90  120  30  40  40  190  190   0  280 Because some patients had the WPW syndrome, the refractory periods of the AV node could not be measured in all studies. 'The effective refractory period measured in 11 patients increased by an average of more than 113-6 ms (P < 0.001). The functional refractory period increased by an average of more than 89-4 ms (P < 0-001).
A pattern suggestive of a dual AV nodal pathway was present before L 9394 administration in 2 patients (cases 1 and 9). L 9394 did not alter the broken aspect of the AV conduction curve in case 9, the electrophysiological properties of both pathways being similarly affected by the drug. But in case 1, a smooth curve was observed during the initial 20 minutes after drug injection. In 2 patients (cases 3 and 5), the injection of L 9394 revealed a dual AV nodal pathway curve that had not been depicted before drug administration. In case 5, this dual pathway curve appeared 20 minutes after injection and persisted until the end of the investigation. In case 2, a patient with AV nodal re-entrant tachycardia, a smooth AV conduction curve was consistently obtained both before and after the administration of L 9394.
In patients without pre-excitation no change was observed in the HV interval. group.bmj.com on June 25, 2017 -Published by http://heart.bmj.com/ Downloaded from subjects (cases 1, 2, 9, 10, 12), the effective refractory period of the VA conduction system lengthened by an average of at least 142 ms.
EFFECTIVE REFRACTORY PERIOD OF RA AND RV
In all but 2 cases, the ERP of the right atrium slightly lengthened. The changes were statistically significant (P < 0 001) but, in absolute values, they appeared trivial. The ERP of the right ventricle failed to show any consistent alteration.
ERP OF ACCESSORY PATHWAY
An accessory pathway was present in 4 cases (2 right-sided; 2 left-sided). The drug was found to have no effect on its effective refractory period either in anterograde or retrograde direction.
MECHANISM OF TACHYCARDIA
In the 3 patients with AV nodal re-entrant tachycardia (cases 1 to 3), and in 3 of the 4 subjects with WPW (cases 5 to 7), episodes of tachycardia could be initiated by electrical stimulation (Table 3) .
In case 1 (Fig. 2) , before the administration of the drug, a single atrial extrastimulus (S2) delivered between 250 and 230 ms after the preceding stimulus (Si) initiated an AV nodal re-entrant tachycardia with a cycle length of 360 ms. In addition, S2 stimuli, delivered from 210 ms to 180 ms after Si, started episodes of atrial flutter with a ventricular cycle length of 400 ms. After L 9394 administration, the jump in the curve plotting the H1H2 against the A1A2 intervals transiently disappeared; it was again observed after a 20-minute period; extrastimuli however could induce only one or two reentrant echo beats, but no sustained tachycardia.
Atrial flutter could not be elicited.
In case 2, AV nodal re-entrant tachycardia could be started only by rapid atrial or ventricular pacing (Fig. 3) . After L 9394, no tachycardia could be induced.
In case 3, supraventricular tachycardia could be initiated by 2 or 3 atrial extrastimuli or by rapid atrial pacing. After drug administration, the ability to induce tachycardia was lost in spite of the unmasking effect of a previously concealed dual AV nodal pathway.
In case 5 (Fig. 4) , a left-sided accessory pathway was associated with a dual AV nodal pathway curve unmasked by L 9394 injection. Episodes of tachycardia with two different cardiac rates (suggesting circuits with AV conduction over either the fast, or the slow AV nodal pathway, and VA conduction over the accessory pathway) could be initiated before drug administration by giving a salvo of at least 3 ventricular extrastimuli, more rarely by 2 atrial premature beats, or by rapid atrial pacing at a rate producing a Wenckebach phenomenon. After the drug, a jump in the AV conduction curve became clearly apparent. Initiation and termination of tachycardia were facilitated. Circus movement tachycardia, using the accessory pathway retrogradely, could be started by either a single ventricular or atrial premature beat with relatively large tachycardia zones (at that time the fast AV nodal pathway had become refractory), by rapid atrial pacing at rates producing a second degree AV block, and by ventricular pacing. The tachycardia could easily be terminated by 2 ventricular premature beats and, with greater difficulty, by a single ventricular extrastimulus, or by 3 atrial premature beats. The tachycardia cycle length was, significantly prolonged after L 9394 (410 ms as compared with 290 or 380 before the injection), this lengthening being in part the result of the exclusive use of the slow AV nodal pathway for anterograde conduction.
In 6 patients with reproducible paroxysmal re-entrant tachycardias, L 9394 was administered during an episode of tachycardia. The injection resulted in termination of the rhythm disorder in all patients with the intranodal type of tachycardia and in 2 of the 3 cases with the WPW syndrome (cases 5 and 7). The heart rate during tachycardia decreased in each subject; this was related to slowing of conduction along the AV node and not to prolongation of the VA conduction time.
OTHER INDICES
Sinus node function tests were not performed during this investigation because of a lack of time during the procedure.
In 2 of the cases, the threshold for atrial stimulation was noted to increase after L 9394 administration. In case 9, for example, the threshold at the end of injection rose to 20 mA. This value was 5 times greater than the control value. It fell to 7 mA 22 minutes later and to 5 mA after 30 minutes. In case 2, the threshold was measured at 7 mA at the end of the injection and at 4 mA 30 minutes later.
In the remaining subjects, no attempt was made to measure systematically the threshold for atrial stimulation. Since stimulation was done at twice the threshold value, any increase of less than 100 per cent would have passed unnoticed.
Arterial blood pressure was monitored throughout the study, in 4 cases by continuous intraarterial pressure recording, and in the remaining instances by repeated measurements by sphygmomanometer. No significant change was observed.
The plasma level of L 9394 was 3-0 ng/ml ± 2.0 at the end of injection and 0 47 ± 0-21 15 minutes later. After the end of injection, the plasma levels showed an exponential decrease. No correlation was observed between the pharmacological effects and the plasma levels of the drug during this initial distribution period (Wellens and Durrer, 1974) .
Discussion
The results of our investigation show that L 9394 is a substance which acts mainly on the AV node. It lengthens the transnodal conduction time as well as the effective and functional refractory periods of the node. As opposed to amiodarone (Touboul et al., 1975; Wellens et al., 1976; Waleffe et al., 1978) , it has no effect on anterograde conduction over the intraventricular conduction system, on ventricular muscle, and accessory pathways.
The observed changes are of the same order of magnitude as those which have been reported previously with ouabain (Wellens et al., 1975; Wu et al., 1975) , propranolol (Wu et al., 1974) , and verapamil (Wellens et al., 1977) .
In contrast to verapamil (Wellens et al., 1977) , L 9394 had some effect on the retrograde VA pathway in several patients. This may of course reflect an action on the AV node but functional changes within the His-Purkinje system used retrogradely cannot be ruled out.
Our observations indicate that L 9394 is a potentially interesting drug for the treatment of tachycardias confined to the AV node. In the 3 patients whom we studied, the episodes of tachycardia were ended by the intravenous injection of the drug. In addition, L 9394 decreased or totally eliminated the echo zones and made the patients lose their ability to develop sustained paroxysmal supraventricular tachycardia during programmed electrical stimulation. The effects in patients with circus movement tachycardia associated with pre-excitation are less clear. In the 3 patients studied, the drug produced slowing of transmission through the anterograde AV nodal part of the tachycardia circuit which resulted in a significant slowing of the cardiac rate during circus movement tachycardia. L 9394 interrupted tachycardia in 2 instances, but failed to protect all 3 patients against reinitiation of tachycardia by premature stimuli. These observations resemble those made in patients with concealed bypasses after administration of ouabain (Wellens et al., 1975; Wu et al., 1975) , propranolol (Wu et a!., 1974) , and verapamil (Wellens et al., 1977) . As pointed out by others (Wellens et al., 1975; Wu etal., 1975) , by producing selective slowing of conduction within the AV node, these drugs, like L 9394, may actually favour the initiation and perpetuation of circus movement tachycardia in the presence of a ventriculoatrial accessory pathway. Delaying conduction through the node increases the chance for a premature impulse to reach the ventricular end ofthe bypass when it is excitable and thus promotes VA conduction over this pathway and initiation as well as perpetuation of tachycardia. This was clearly shown in case 5 of this series in whom an accessory bypass as well as a dual nodal pathway were simultaneously present. Prolongation of the conduction time especially along the slow nodal pathway made it much easier to induce the tachycardia after drug administration.
Drug induced changes of the pattern of atrioventricular conduction have previously been re- (Wu et al., 1974; Wellens et al., 1975 Wellens et al., , 1977 . Two different situations were encountered in this series. In 2 patients, a dual AV nodal pathway was shown only after administration of L 9394. In one other case, a dual pathway curve was identified before drug administration, but changed into a smooth curve afterwards. The possible explanations for such a phenomenon have been discussed previously (Wellens et al., 1975) .
In summary, it is apparent that L 9394 does not share all the pharmacological properties of amiodarone and in spite of its possibly better tolerance, it will not completely replace amiodarone. As it has little effect on the atrial and ventricular muscles and on the accessory pathways it is unlikely that L 9394 will be as effective as amiodarone on a large spectrum of arrhythmias. We want to stress however that our data were obtained after intravenous administration of L 9394. Little is known of the pharmacokinetics ofthis substance in the human. In addition, previous experience has indicated that the effect of intravenous amiodarone is different from that obtained after long-term oral administration (Berkman et al., 1975) . In view of this, chronic studies (Wu et al., 1977) on the effect of L 9394 administered orally are needed before any definite conclusion can be drawn regarding the clinical usefulness of this drug.
